Alluvi, formerly BI 4744, represents a significant advance in weight management therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP targets demonstrates impressive efficacy in patient studies, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/